• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

针对 IGF 系统成分的抗体类治疗药物。

Antibody-based therapeutics against components of the IGF system.

机构信息

Protein Interactions Group; FNLCF; NIH; Frederick, MD USA.

出版信息

Oncoimmunology. 2012 Nov 1;1(8):1390-1391. doi: 10.4161/onci.20925.

DOI:10.4161/onci.20925
PMID:23243603
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3518512/
Abstract

The insulin-like growth factor I (IGF-I) receptor (IGF-1R) is overexpressed in most human neoplasms tested so far. Many tumors in young patients produce high levels of the IGF-1R ligands, IGF-I and IGF-II. Given the complexity of the IGF signaling pathway, its complete inhibition may require combination therapies with antibodies targeting both IGF-1R and IGF-II.

摘要

胰岛素样生长因子 I (IGF-I) 受体 (IGF-1R) 在迄今为止测试的大多数人类肿瘤中均过度表达。许多年轻患者的肿瘤产生高水平的 IGF-1R 配体，IGF-I 和 IGF-II。鉴于 IGF 信号通路的复杂性，完全抑制可能需要联合使用针对 IGF-1R 和 IGF-II 的抗体的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84c/3518512/83151e5708af/onci-1-1390-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84c/3518512/83151e5708af/onci-1-1390-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84c/3518512/83151e5708af/onci-1-1390-g1.jpg

相似文献

1
Antibody-based therapeutics against components of the IGF system.针对 IGF 系统成分的抗体类治疗药物。
Oncoimmunology. 2012 Nov 1;1(8):1390-1391. doi: 10.4161/onci.20925.
2
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.双 IGF-I/II 中和抗体 MEDI-573 能够强烈抑制 IGF 信号和肿瘤生长。
Cancer Res. 2011 Feb 1;71(3):1029-40. doi: 10.1158/0008-5472.CAN-10-2274. Epub 2011 Jan 18.
3
Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.胰岛素样生长因子信号作为胰腺癌的治疗靶点。
Anticancer Agents Med Chem. 2011 Jun;11(5):427-33. doi: 10.2174/187152011795677454.
4
Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.胰岛素样生长因子-1受体抑制通过表皮生长因子受体/HER3/AKT信号通路诱导一种耐药机制：肝细胞癌中同时靶向胰岛素样生长因子-1受体和表皮生长因子受体的理论基础。
Clin Cancer Res. 2009 Sep 1;15(17):5445-56. doi: 10.1158/1078-0432.CCR-08-2980. Epub 2009 Aug 25.
5
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.胰岛素受体在功能上增强多阶段肿瘤进展，并赋予对 IGF-1R 靶向治疗的内在抗性。
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10791-8. doi: 10.1073/pnas.0914076107. Epub 2010 May 10.
6
R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.R1507，一种抗胰岛素样生长因子-1 受体（IGF-1R）抗体，以及 Ewing 肉瘤中的 EWS/FLI-1 siRNA：在 IGF/IGFR/Akt 轴上的交汇。
PLoS One. 2011;6(10):e26060. doi: 10.1371/journal.pone.0026060. Epub 2011 Oct 11.
7
IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.IGF 系统靶向治疗：卵巢癌的治疗机会。
Cancer Treat Rev. 2017 Nov;60:90-99. doi: 10.1016/j.ctrv.2017.08.012. Epub 2017 Sep 8.
8
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.XGFR*，一种新型亲和力成熟的双特异性抗体，靶向胰岛素样生长因子-1受体（IGF-1R）和表皮生长因子受体（EGFR），具有联合信号抑制和增强免疫激活作用，用于治疗胰腺癌。
MAbs. 2016 May-Jun;8(4):811-27. doi: 10.1080/19420862.2016.1160989. Epub 2016 Mar 16.
9
Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.在单克隆抗体西妥昔单抗存在的情况下，胰岛素样生长因子1受体介导表皮生长因子受体的酪氨酸845磷酸化。
BMC Cancer. 2016 Oct 6;16(1):773. doi: 10.1186/s12885-016-2796-x.
10
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.通过抑制胰岛素样生长因子（IGF）受体信号传导来治疗血液系统恶性肿瘤和实体瘤。
Expert Rev Anticancer Ther. 2005 Jun;5(3):487-99. doi: 10.1586/14737140.5.3.487.

引用本文的文献

1
An insulin growth factor-I/II-neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth.一种胰岛素生长因子-I/II中和单克隆抗体与表皮生长因子受体抑制剂联合使用可有效抑制肿瘤细胞生长。
J Cancer. 2022 Mar 21;13(6):1830-1836. doi: 10.7150/jca.69064. eCollection 2022.
2
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).卡培他滨和拉帕替尼联合或不联合 IMC-A12（西妥昔单抗）治疗曲妥珠单抗和化疗治疗后 HER2 阳性晚期乳腺癌患者的随机 II 期试验：NCCTG N0733（Alliance）。
Breast Cancer Res Treat. 2021 Jul;188(2):477-487. doi: 10.1007/s10549-021-06221-8. Epub 2021 Apr 14.
3

本文引用的文献

1
Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics.针对胰岛素样生长因子 II 上非重叠表位的人源单克隆抗体作为一种新型候选癌症治疗药物。
Mol Cancer Ther. 2012 Jul;11(7):1400-10. doi: 10.1158/1535-7163.MCT-12-0172. Epub 2012 May 2.
2
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.胰岛素样生长因子受体（IGF-1R）抗体西妥昔单抗联合 mTOR 抑制剂替西罗莫司治疗难治性尤文氏肉瘤家族肿瘤患者。
Clin Cancer Res. 2012 May 1;18(9):2625-31. doi: 10.1158/1078-0432.CCR-12-0061. Epub 2012 Mar 31.
3
Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma.解析尤因肉瘤中胰岛素样生长因子（IGF）通路抑制的耐药机制
Cancers (Basel). 2020 Nov 29;12(12):3568. doi: 10.3390/cancers12123568.
4
Therapeutic Targeting of the IGF Axis.IGF 轴的治疗靶向。
Cells. 2019 Aug 14;8(8):895. doi: 10.3390/cells8080895.
5
A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells.一种双特异性 IGF-I/II 人源工程抗体结构域抑制乳腺癌细胞中的 IGF 信号。
Int J Biol Sci. 2018 May 21;14(7):799-806. doi: 10.7150/ijbs.25928. eCollection 2018.
6
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.胰岛素样生长因子（IGF）通路在癌症中的靶向治疗：IGF 轴的作用和未来联合研究的机会。
Target Oncol. 2017 Oct;12(5):571-597. doi: 10.1007/s11523-017-0514-5.
7
Trial Watch: Proteasomal inhibitors for anticancer therapy.试验观察：用于抗癌治疗的蛋白酶体抑制剂
Mol Cell Oncol. 2014 Dec 1;2(2):e974463. doi: 10.4161/23723556.2014.974463. eCollection 2015 Apr-Jun.
8
Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.儿科骨肉瘤：我们对肿瘤生物学的理解进展及其对治疗的意义
Paediatr Drugs. 2015 Aug;17(4):257-71. doi: 10.1007/s40272-015-0134-4.
9
A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.一种双特异性抗IGF-1/IGF-2人单克隆抗体单独及与替西罗莫司联合用于神经母细胞瘤治疗
Int J Cancer. 2015 Nov 1;137(9):2243-52. doi: 10.1002/ijc.29588. Epub 2015 May 19.
Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).
FIGITEUMAB 治疗复发性和/或转移性头颈部鳞状细胞癌的 II 期研究：临床疗效和分子应答（GORTEC 2008-02）。
Ann Oncol. 2012 Aug;23(8):2153-2161. doi: 10.1093/annonc/mdr574. Epub 2012 Jan 10.
4
Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.IGF-1 受体靶向抗体 SCH717454 的强烈抑制作用可被 IGF-2 逆转。
Mol Cancer Ther. 2012 Mar;11(3):649-59. doi: 10.1158/1535-7163.MCT-11-0575. Epub 2011 Dec 21.
5
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.R1507，一种针对胰岛素样生长因子 1 受体的单克隆抗体，用于治疗复发性或难治性尤文肉瘤家族肿瘤的患者：来自 Sarcoma Alliance for Research through Collaboration 协作研究的 II 期结果。
J Clin Oncol. 2011 Dec 1;29(34):4541-7. doi: 10.1200/JCO.2010.34.0000. Epub 2011 Oct 24.
6
Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity.与人胰岛素样生长因子 I 和 II 具有皮摩尔亲和力的人源单克隆抗体片段。
Mol Cancer Ther. 2011 Sep;10(9):1677-85. doi: 10.1158/1535-7163.MCT-11-0281. Epub 2011 Jul 12.
7
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.双 IGF-I/II 中和抗体 MEDI-573 能够强烈抑制 IGF 信号和肿瘤生长。
Cancer Res. 2011 Feb 1;71(3):1029-40. doi: 10.1158/0008-5472.CAN-10-2274. Epub 2011 Jan 18.
8
A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo.一种针对胰岛素样生长因子-II 的人源单克隆抗体可在体外和体内阻断人肝癌细胞系的生长。
Mol Cancer Ther. 2010 Jun;9(6):1809-19. doi: 10.1158/1535-7163.MCT-09-1134. Epub 2010 Jun 1.
9
Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function.新型人源单克隆抗体，可有效抑制胰岛素样生长因子（IGF）-II与I型IGF受体的信号转导功能。
Mol Cancer Ther. 2006 Jan;5(1):114-20. doi: 10.1158/1535-7163.MCT-05-0252.
10
The IgG Fc receptor family.IgG Fc受体家族。
Ann Hematol. 1998 Jun;76(6):231-48. doi: 10.1007/s002770050396.